Answers are grounded in this paper and cite their sources.
EPd demonstrated a statistically significant improvement in OS versus Pd in patients with RRMM previously treated with lenalidomide and a PI who had disease refractory to last therapy. In this setting, ELOQUENT-3 is the first randomized study of a triplet regimen incorporating a monoclonal antibody and Pd to improve both PFS and OS significantly.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: